Therapies using bortezomib and immunomodulatory agents after autologous hematopoietic cell transplantation (HCT) for patients with high-risk (HR) multiple myeloma appears to contribute to improved HCT outcomes, with 3-year overall survival (OS) of 81%.
Researchers retrospectively studied 715 patients with multiple myeloma who underwent upfront autologous HCT between 2008 and 2012 and whose outcomes were reported to the CIBMTR® (Center for International Blood and Marrow Transplant Research). Outcomes were studied separately for patients receiving post-HCT therapy with bortezomib and immunomodulatory agents and those patients who did not.
Three-year OS for HR patients with and without post-HCT therapy were 81% (95% CI, 70 to 90) vs. 48% (95% CI, 30 to 65) compared with 88% (95% CI, 84 to 92) and 79% (95% CI, 73 to 85) in non-high-risk (nHR) patients with and without post-HCT therapy, respectively. Among patients receiving post-HCT therapy, there was no difference in OS between HR and nHR patients (p=0.08).
The researchers concluded that using bortezomib and immunomodulatory agents after autologous HCT appeared to improve the outcomes of patients with high-risk multiple myeloma.